SCHEMBL26075531

SCHEMBL26075531

CCc1cc(-c2ccc(-c3ccc(OC)cc3)cc2)nc2ccc(C)cc12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.60
▸ DHODH Q02127 3/20 0.56
▸ ESRRB O95718 1/20 0.56
▸ ESR1 P03372 1/20 0.56
▸ ESRRA P11474 1/20 0.56
▸ ESR2 Q92731 1/20 0.56
▸ KDM4E B2RXH2 7/20 0.53
▸ ALDH1A1 P00352 5/20 0.53
▸ HPGD P15428 3/20 0.53
▸ GAA P10253 2/20 0.53
▸ HSD17B10 Q99714 2/20 0.53
▸ GLA P06280 2/20 0.50
▸ L3MBTL1 Q9Y468 2/20 0.50
▸ TP53 P04637 2/20 0.50
▸ PLA2G2A P14555 1/20 0.50
▸ ACP1 P24666 1/20 0.49
▸ ACACA Q13085 1/20 0.49
▸ LMNA P02545 1/20 0.49
▸ HTT P42858 1/20 0.49
▸ PKM P14618 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26075525 0.88 ESR1 (0.54) MAPTDHODHESRRBESR1ESRRA
SCHEMBL26075632 0.88 MAPT (0.48) MAPTDHODHESRRBESR1ESRRA
SCHEMBL26075533 0.86 PLA2G2A (0.63) MAPTDHODHESRRBESR1ESRRA
SCHEMBL24858379 0.82 MAPT (0.78) MAPTDHODHKDM4EALDH1A1HPGD
SCHEMBL28264925 0.80 MAPT (0.60) MAPTDHODHESRRBESR1ESRRA
SCHEMBL21799200 0.78 ACACA (0.74) MAPTDHODHKDM4EALDH1A1HPGD
SCHEMBL27986490 0.78 ACACA (0.74) MAPTDHODHKDM4EALDH1A1HPGD
SCHEMBL26075631 0.78 ESR1 (0.43) MAPTDHODHESRRBESR1ESRRA
SCHEMBL26075665 0.77 ESRRB (0.40) MAPTDHODHESRRBESR1ESRRA
SCHEMBL7944075 0.77 KDM4E (0.70) MAPTDHODHESRRBESR1ESRRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT OHIO STATE INNOVATION FOUNDATION (US) 2023-09-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT DHODH, CD38, DPYD MAPT 2689/4885DHODH 1/4885ESRRB 4671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback